Stock listing
NASDAQ:ACTU Actuate Therapeutics, Inc. Stock
Home listing (NASDAQ) of Actuate Therapeutics, Inc.
Follow Actuate Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ACTU
$0.225 USD -0.020 (-8.3%)
Close on Nov 20, 2026
- Day range
- $0.200 – $0.248 USDNov 20, 2026
- Volume
- 629,804 sharesNov 20, 2026
- Market cap
- $13.60M USDAt the close on Nov 20, 2026 · price × 60.38M shares outstanding
- 52-week range
- $0.200 – $7.900 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $429,316 USDMedian day 285,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ACTU · Home | $0.225 USD | -0.020 (-8.3%) | 629,804 | $0.200 | $0.248 | $0.200 | $0.246 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ACTU · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.225 | -0.020 | -8.3% | $0.200 | $0.248 | $0.200 | 629,804 | |
| $0.246 | -0.006 | -2.4% | $0.281 | $0.320 | $0.240 | 16,133,689 | |
| $0.252 | -0.016 | -6.1% | $0.266 | $0.295 | $0.229 | 194,146 | |
| $0.268 | -0.017 | -6.1% | $0.288 | $0.302 | $0.255 | 231,014 | |
| $0.285 | -0.011 | -3.6% | $0.332 | $0.332 | $0.284 | 173,897 | |
| $0.296 | -0.006 | -2.1% | $0.330 | $0.350 | $0.290 | 155,800 | |
| $0.302 | +0.005 | +1.8% | $0.300 | $0.330 | $0.300 | 94,578 | |
| $0.297 | -0.017 | -5.3% | $0.318 | $0.350 | $0.290 | 174,313 | |
| $0.314 | -0.015 | -4.6% | $0.341 | $0.350 | $0.300 | 300,033 | |
| $0.329 | +0.002 | +0.6% | $0.327 | $0.350 | $0.301 | 517,894 | |
| $0.327 | -0.043 | -11.6% | $0.355 | $0.370 | $0.320 | 479,183 | |
| $0.370 | +0.020 | +5.7% | $0.360 | $0.380 | $0.341 | 303,534 | |
| $0.350 | +0.008 | +2.3% | $0.360 | $0.374 | $0.338 | 312,301 | |
| $0.342 | +0.007 | +2.1% | $0.380 | $0.380 | $0.335 | 295,455 | |
| $0.335 | -0.036 | -9.7% | $0.380 | $0.385 | $0.330 | 489,500 | |
| $0.371 | -0.012 | -3.1% | $0.383 | $0.420 | $0.360 | 814,000 | |
| $0.383 | -0.017 | -4.3% | $0.404 | $0.407 | $0.361 | 715,700 | |
| $0.400 | -0.128 | -24.2% | $0.379 | $0.438 | $0.350 | 2,210,500 | |
| $0.528 | +0.053 | +11.2% | $0.507 | $0.600 | $0.475 | 236,200 | |
| $0.475 | -0.041 | -7.9% | $0.530 | $0.556 | $0.450 | 255,200 | |
| $0.516 | -0.046 | -8.2% | $0.570 | $0.600 | $0.470 | 335,000 | |
| $0.562 | -0.054 | -8.8% | $0.598 | $0.638 | $0.560 | 220,400 | |
| $0.616 | +0.017 | +2.8% | $0.593 | $0.662 | $0.546 | 166,700 | |
| $0.599 | -0.006 | -1.0% | $0.661 | $0.710 | $0.520 | 727,300 | |
| $0.605 | +0.105 | +21.0% | $0.493 | $0.640 | $0.470 | 926,200 | |
| $0.500 | +0.066 | +15.2% | $0.457 | $0.550 | $0.433 | 472,100 | |
| $0.434 | -0.032 | -6.9% | $0.480 | $0.490 | $0.410 | 439,400 | |
| $0.466 | -0.178 | -27.6% | $0.660 | $0.660 | $0.438 | 967,700 | |
| $0.644 | +0.034 | +5.6% | $0.600 | $0.680 | $0.600 | 285,900 | |
| $0.610 | -0.069 | -10.2% | $0.641 | $0.680 | $0.610 | 295,000 | |
| $0.679 | -0.045 | -6.2% | $0.682 | $0.724 | $0.621 | 324,500 | |
| $0.724 | -0.088 | -10.8% | $0.643 | $0.724 | $0.615 | 637,900 | |
| $0.812 | -0.063 | -7.2% | $0.890 | $0.890 | $0.760 | 337,700 | |
| $0.875 | +0.056 | +6.8% | $0.850 | $0.926 | $0.801 | 201,900 | |
| $0.819 | -0.070 | -7.9% | $0.930 | $0.950 | $0.800 | 91,900 | |
| $0.889 | +0.109 | +14.0% | $0.798 | $0.960 | $0.765 | 494,100 | |
| $0.780 | +0.094 | +13.7% | $0.710 | $0.830 | $0.690 | 409,600 | |
| $0.686 | -0.050 | -6.8% | $0.738 | $0.748 | $0.683 | 111,000 | |
| $0.736 | +0.056 | +8.2% | $0.685 | $0.738 | $0.604 | 276,900 | |
| $0.680 | +0.060 | +9.7% | $0.650 | $0.750 | $0.640 | 382,800 | |
| $0.620 | -0.112 | -15.3% | $0.750 | $0.750 | $0.610 | 272,500 | |
| $0.732 | -0.075 | -9.3% | $0.800 | $0.869 | $0.720 | 222,000 | |
| $0.807 | -0.100 | -11.0% | $0.900 | $0.930 | $0.800 | 187,200 | |
| $0.907 | -0.074 | -7.5% | $0.987 | $1.020 | $0.890 | 274,500 | |
| $0.981 | -0.014 | -1.4% | $1.000 | $1.030 | $0.960 | 113,100 | |
| $0.995 | -0.002 | -0.2% | $1.040 | $1.050 | $0.963 | 174,500 | |
| $0.997 | +0.013 | +1.3% | $1.000 | $1.050 | $0.940 | 208,800 | |
| $0.984 | -0.046 | -4.5% | $1.040 | $1.060 | $0.980 | 148,400 | |
| $1.030 | -0.040 | -3.7% | $1.080 | $1.090 | $0.990 | 259,000 | |
| $1.070 | -0.080 | -7.0% | $1.150 | $1.230 | $1.030 | 239,600 | |
| $1.150 | -0.110 | -8.7% | $1.250 | $1.280 | $1.130 | 204,400 | |
| $1.260 | -0.110 | -8.0% | $1.380 | $1.400 | $1.260 | 119,800 | |
| $1.370 | -0.110 | -7.4% | $1.460 | $1.480 | $1.330 | 210,000 | |
| $1.480 | +0.110 | +8.0% | $1.450 | $1.730 | $1.330 | 1,322,900 | |
| $1.370 | +0.070 | +5.4% | $1.390 | $1.460 | $1.260 | 474,000 | |
| $1.300 | -0.240 | -15.6% | $1.500 | $1.550 | $1.300 | 332,300 | |
| $1.540 | +0.020 | +1.3% | $1.490 | $1.580 | $1.410 | 129,600 | |
| $1.520 | -0.135 | -8.2% | $1.640 | $1.650 | $1.460 | 274,700 | |
| $1.655 | -0.035 | -2.1% | $1.690 | $1.780 | $1.630 | 231,300 | |
| $1.690 | -0.090 | -5.1% | $1.770 | $1.796 | $1.630 | 366,100 | |
| $1.780 | +0.200 | +12.7% | $1.730 | $1.970 | $1.570 | 3,300,900 | |
| $1.580 | +0.350 | +28.5% | $1.240 | $1.580 | $1.200 | 589,187 | |
| $1.230 | -0.040 | -3.1% | $1.280 | $1.310 | $1.181 | 179,285 | |
| $1.270 | +0.040 | +3.3% | $1.220 | $1.342 | $1.180 | 274,700 | |
| $1.230 | +0.170 | +16.0% | $1.060 | $1.340 | $1.010 | 939,000 |
- Ticker
- NASDAQ:ACTU
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 18, 2026
Actuate Therapeutics Reports Positive Monotherapy Data in Aggressive Melanoma Preclinical Model with Daily Dosing of Elraglusib Oral Tablet at ENA 2026
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 16 slides
Latest news
Actuate Therapeutics Reports Positive Monotherapy Data in Aggressive Melanoma Preclinical Model with Daily Dosing of Elraglusib Oral Tablet at ENA 2026
Nov 18, 2026
Closed $0.246 (-2.4%) on Nov 18, 2026
Actuate Therapeutics to Present Promising Preclinical Data Demonstrating Antitumor and Immune Activation Activity of Elraglusib Oral Tablet in Advanced Melanoma Models at ENA 2026
Nov 4, 2026
Closed $0.37 (+5.7%) on Nov 4, 2026
Actuate Therapeutics Receives U.S. Notice of Allowance for Patent Covering Elraglusib Oral Tablets
Nov 2, 2026
Closed $0.342 (+2.1%) on Nov 2, 2026
Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering
Oct 27, 2026
Closed $0.40 (-24.2%) on Oct 27, 2026
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 9, 2026
Closed $1.15 (-8.7%) on Sep 10, 2026
Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
Jun 9, 2026
Closed $2.01 (+10.4%) on Jun 9, 2026
Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer
Jun 1, 2026
Closed $1.99 (-1.5%) on Jun 1, 2026
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
May 11, 2026
Closed $2.98 (-9.8%) on May 11, 2026
Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors
May 6, 2026
Closed $2.99 (-2.6%) on May 6, 2026
Actuate Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 19 in the last 12 months · 45 in all · newest Nov 18, 2026 · oldest 2024
- Decks
- 16 decks · latest November 2026
Where Actuate Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ACTU · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ACTU | BOATS | United States | USD |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $11.50M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.75
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Actuate Therapeutics, Inc. · NASDAQ:ACTU | US$13.60M | US$11.50M | n/a | n/a | n/a | n/a | n/a | n/a | 1.75 |
| Citius Pharmaceuticals, Inc. · NASDAQ:CTXR | US$13.96M | −US$3.05M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 1.71 |
| TaiwanJ Pharmaceuticals Co., Ltd. · TPEX:6549 | US$13.69M | US$11.86M | n/a | n/a | n/a | 7.0× | n/a | 0.0× | n/a |
| BeyondSpring, Inc. · NASDAQ:BYSI | US$13.57M | US$12.99M | 0.3× | n/a | n/a | 0.9× | n/a | 0.0× | 1.31 |
| Acumen Pharmaceuticals, Inc. · NASDAQ:ABOS | US$13.49M | −US$38.84M | n/a | n/a | n/a | 0.4× | n/a | 0.8× | 1.45 |
| Pharma Equity Group A/S Class A · OMXCOP:PEG | US$13.48M | US$15.05M | n/a | n/a | 52.8× | 3.6× | n/a | 0.4× | n/a |
| BioInvent International AB · OMXSTO:BINV | US$13.46M | −US$6.63M | n/a | −1.7× | n/a | 0.7× | n/a | 0.1× | n/a |
| Thalia Therapeutics PLC · LSE:THAT | US$13.37M | US$11.40M | n/a | 1,199× | n/a | 4.2× | n/a | 0.0× | n/a |
| Celyad Oncology SA · EURONEXT:CYAD | US$13.31M | US$13.21M | 14.6× | 573× | n/a | 9.7× | n/a | 0.0× | n/a |
| Defence Therapeutics Inc Class A · CSE:DTC | US$13.27M | US$13.16M | n/a | n/a | n/a | 5.4× | n/a | 0.5× | 0.74 |
| Diamyd Medical AB Class B · OMXSTO:DMYD_B | US$13.22M | −US$16.67M | n/a | −357× | n/a | 0.6× | n/a | 0.0× | n/a |
| Median of the others | US$13.47M | US$11.63M | 7.5× | 286× | 52.8× | 2.2× | 0.0× | 1.38 |
Forecasts
3 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 11.68 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.73 · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Daniel M. Schmitt | President & Chief Executive Officer |
Board
| Director | Role |
|---|---|
| Aaron G.L. Fletcher | Chairman |
| Amy Ronneberg | Director |
| Dan Zabrowski | Director |
| Daniel M. Schmitt | President & Chief Executive Officer |
| Jason Keyes | Director |
| Martin H. Huber | Director |
| Roger Sawhney | Director |
| Todd Thomson | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 · After close | −6.1% |
| Q2 2026 | Aug 14, 2026 · After close | −2.0% |
| Q1 2026 | May 14, 2026 · After close | −9.7% |
| Q4 2025 | Mar 31, 2026 · After close | −9.1% |
| Q3 2025 | Nov 13, 2025 · After close | +0.5% |
| Q2 2025 | Aug 14, 2025 · After close | −1.2% |
| Q1 2025 | May 15, 2025 · After close | +8.1% |
| Q4 2024 | Feb 26, 2025 | −1.8% |
| Q3 2024 | Nov 27, 2024 | −9.7% |
| Q2 2024 | Aug 28, 2024 | +1.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 16 slides | November 2026 |
| Investor Presentation (September 2026) | Investor deck | 17 slides | September 2026 |
| Investor Presentation (May 2026) | Investor deck | 18 slides | May 11, 2026 |
| Investor Presentation (January 2026) | Investor deck | 34 slides | January 2026 |
| Investor Presentation (November 2025) | Investor deck | 29 slides | November 2025 |
| Investor Presentation (August 2025) | Investor deck | 25 slides | August 2025 |
| Investor Presentation (May 2025) | Investor deck | 25 slides | May 31, 2025 |
| Investor Presentation (March 2025) | Investor deck | 21 slides | March 2025 |
| Investor Presentation (January 2025) | Investor deck | 21 slides | January 2025 |
| Investor Presentation (December 2024) | Investor deck | 23 slides | December 2024 |
All 16 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2024) | Investor deck | 22 slides | November 2024 |
| Investor Presentation (September 2024) | Investor deck | 22 slides | September 2024 |
| IPO Roadshow (July 2024) | IPO roadshow | 27 slides | Jul 23, 2024 |
| Investor Presentation (July 2024) | Investor deck | 24 slides | July 2024 |
| IPO Roadshow (June 2024) | IPO roadshow | 25 slides | Jun 11, 2024 |
| STIFEL 2023 Targeted Oncology Days | Conference | 16 slides | Apr 26, 2023 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and warrants Announced: about US$11M · US$0.71 a share · 1 warrant at US$0.45 for 60 months · Newbridge Securities Corporation Dealers: Newbridge Securities Corporation (lead) Use of proceeds: Working capital and general corporate purposes | Oct 27, 2026 |
| Public offering of common stock Closed: US$17.25M raised · US$7 a share · Lucid Capital Markets +1 Dealers: Lucid Capital Markets (lead), Titan Partners Group, a division of American Capital Partners Use of proceeds: Working capital and general corporate purposes | Sep 11, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$8.00 a share on Aug 12, 2024.
- Price
- US$8.00 a share
- Shares offered
- 2,800,000 shares of common stock
- Offering size
- US$22.4 million
- Underwriters' option
- Up to 420,000 more shares
- Listing
- ACTU on the Nasdaq Global Market
- Underwriters
- Titan Partners Group, Newbridge Securities Corporation · In the order on the cover
- Shares delivered
- On or about Aug 14, 2024
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Mar 4, 2024 |
| Filed publicly | May 24, 2024 |
| Amended 5 times | Newest Jul 23, 2024 |
| Shares registered with an exchange | Jun 20, 2024 |
| Declared effective by the SEC | Aug 12, 2024 |
| Final prospectus, with the price | Aug 13, 2024 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Aug 13, 2024 |
| EFFECT · Notice that a registration is effective | Aug 12, 2024 |
| CERT · Exchange's certificate of listing | Aug 12, 2024 |
| CORRESP · Letter to the SEC | Aug 12, 2024 |
| CORRESP · Letter to the SEC | Aug 12, 2024 |
| 8-A12B/A · Registration of shares for listing on an exchange, amended | Aug 12, 2024 |
| CORRESP · Letter to the SEC | Aug 2, 2024 |
| CORRESP · Letter to the SEC | Aug 2, 2024 |
| CORRESP · Letter to the SEC | Jul 30, 2024 |
| CORRESP · Letter to the SEC | Jul 30, 2024 |
All 46 filings
Open IPO · From the cover of the final prospectus (424B4) filed Aug 13, 2024
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Research and development | 10.3M | 18.7M | 21.7M | 16.4M |
| Selling, general and administrative | 12.2M | 6.48M | 3.27M | 3.82M |
| Operating income | -22.5M | -25.2M | -25.0M | -20.2M |
| Depreciation and amortization | 25.2M | 25.0M | 20.2M | |
| EBITDA | 0 | -1 | 0 | |
| Interest expense | 20.3K | 18.7K | 43.6K | 16.2K |
| Income before tax | -22.2M | -27.3M | -24.7M | -20.2M |
| Income tax | 800 | 800 | 0 | |
| Net income | -22.2M | -27.3M | -24.7M | -20.2M |
| Earnings per share, basic | -1.06 | -3.26 | -17.24 | -1.34 |
| Earnings per share, diluted | -1.06 | -3.26 | -17.24 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | 13.2M | 8.64M | 2.96M | 20.4M |
| Current assets | 13.6M | 9.21M | 3.00M | 20.5M |
| Total assets | 14.0M | 9.32M | 3.00M | 20.5M |
| Accounts payable | 1.52M | 1.92M | 3.42M | 2.13M |
| Current liabilities | 5.71M | 8.80M | 6.92M | 4.34M |
| Total debt | 405.0K | 405.0K | 405.0K | |
| Total liabilities | 6.11M | 9.21M | 8.44M | 5.65M |
| Shareholders' equity | 7.92M | 104.2K | -99.6M | 14.8M |
| Shares outstanding | 23.2M | 19.5M | 1.69M | 15.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | -19.2M | -21.8M | -21.6M | -17.8M |
| Capital spending | 0 | 0 | 0 | 0 |
| Free cash flow | -19.2M | -21.8M | -21.6M | -17.8M |
| Cash from financing | 23.7M | 27.5M | 4.13M | 19.3M |
| Share buybacks | 485.2K | |||
| Change in cash | 4.52M | 5.68M | -17.5M | 1.46M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 30, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 30, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 29, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 28, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Oct 28, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Oct 27, 2026 | Other filings | SEC |
All 193 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-1/A · Registration statement, amended | Oct 19, 2026 | Offer document | SEC |
| S-1/A · Registration statement, amended | Oct 14, 2026 | Offer document | SEC |
| FWP · Free writing prospectus | Oct 8, 2026 | Offer document | SEC |
| S-1 · Registration statement | Oct 6, 2026 | Offer document | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 17, 2026 | Current report | SEC |
| DRS · Draft registration statement | Jun 8, 2026 | Offer document | SEC |
| 8-K · Current report | May 22, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | May 14, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | May 6, 2026 | Insider trade | SEC |
| DEFA14A · Additional proxy material | May 6, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 6, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 22, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 9, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 6, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 6, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| 10-K · Annual report | Mar 26, 2026 | Annual report | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 17, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Dec 11, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 28, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Nov 28, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 21, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Sep 10, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Sep 10, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Sep 9, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 9, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 4, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 2, 2025 | Other filings | SEC |
| S-3 · Registration statement | Sep 2, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Aug 26, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Aug 18, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Aug 5, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Aug 4, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 31, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 31, 2025 | Other filings | SEC |
| S-1 · Registration statement | Jul 25, 2025 | Offer document | SEC |
| D | Jul 7, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 30, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 26, 2025 | Material contract | SEC |
| 8-K · Current report | Jun 5, 2025 | Current report | SEC |
| 8-K · Current report | Jun 2, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 27, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 8-K · Current report | May 23, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | May 15, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Apr 17, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Apr 16, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 14, 2025 | Other filings | SEC |
| D | Apr 10, 2025 | Other filings | SEC |
| DEFA14A · Additional proxy material | Apr 8, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 8, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Apr 1, 2025 | Other filings | SEC |
| S-1 · Registration statement | Mar 28, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 28, 2025 | Material contract | SEC |
| 10-K · Annual report | Mar 13, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 7, 2025 | Current report | SEC |
| 8-K · Current report | Dec 17, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Sep 24, 2024 | Quarterly report | SEC |
| SEC STAFF LETTER | Aug 27, 2024 | Other filings | SEC |
| 4/A · Change in ownership, amended | Aug 20, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Aug 20, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Aug 20, 2024 | Insider trade | SEC |
| SC 13D · Big-stake notice | Aug 19, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Aug 19, 2024 | Current report | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 14, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 14, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Aug 14, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 14, 2024 | Management or board change | SEC |
| POS EX | Aug 13, 2024 | Other filings | SEC |
| 424B4 · Prospectus | Aug 13, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Aug 13, 2024 | Other filings | SEC |
| 3 · Initial statement of ownership | Aug 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 12, 2024 | Insider trade | SEC |
| CERT · Exchange's certificate of listing | Aug 12, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 12, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 12, 2024 | Other filings | SEC |
| 8-A12B/A · Registration of shares for listing on an exchange, amended | Aug 12, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 2, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 2, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 30, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 30, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 26, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 26, 2024 | Other filings | SEC |
| FWP · Free writing prospectus | Jul 23, 2024 | Offer document | SEC |
| S-1/A · Registration statement, amended | Jul 23, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 19, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 19, 2024 | Other filings | SEC |
| FWP · Free writing prospectus | Jul 19, 2024 | Offer document | SEC |
| S-1/A · Registration statement, amended | Jul 19, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 17, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 17, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jul 16, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 15, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 15, 2024 | Other filings | SEC |
| FWP · Free writing prospectus | Jun 21, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 21, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jun 21, 2024 | Offer document | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Jun 20, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 18, 2024 | Other filings | SEC |
| FWP · Free writing prospectus | Jun 11, 2024 | Offer document | SEC |
| S-1/A · Registration statement, amended | Jun 11, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 11, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 31, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 24, 2024 | Other filings | SEC |
| S-1 · Registration statement | May 24, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | May 20, 2024 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | May 10, 2024 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | May 10, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | May 8, 2024 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Apr 30, 2024 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Apr 30, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Apr 19, 2024 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Apr 9, 2024 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Apr 9, 2024 | Offer document | SEC |
| SEC STAFF LETTER | Apr 4, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 1, 2024 | Other filings | SEC |
| D | Mar 6, 2024 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Mar 4, 2024 | Other filings | SEC |
| DRS · Draft registration statement | Mar 4, 2024 | Offer document | SEC |
| D/A | Dec 15, 2022 | Other filings | SEC |
| D | Oct 19, 2022 | Other filings | SEC |
| D | Dec 10, 2020 | Other filings | SEC |
| D/A | Nov 14, 2019 | Other filings | SEC |
| D | Oct 15, 2019 | Other filings | SEC |
| D | May 13, 2019 | Other filings | SEC |
| D | Sep 12, 2018 | Other filings | SEC |
| D | Mar 20, 2017 | Other filings | SEC |
| D | Feb 2, 2017 | Other filings | SEC |
| D | Oct 8, 2015 | Other filings | SEC |
Cap table
Built by 6ix from Actuate Therapeutics, Inc.’s releases · as of Nov 13, 2026
- Common shares
- 60,382,824
- Fully diluted
- 60,382,824
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 60,382,824 | Nov 13, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 13, 2026 | 60,382,824 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Aaron G.L. Fletcher Other companies: Cognition Therapeutics, Inc. (Director · Since at least Oct 7, 2021); IN8bio, Inc. (Director · Aug 16, 2022 – Dec 12, 2022 · Past); TFF Pharmaceuticals Inc (Director · Oct 24, 2019 – Dec 29, 2022 · Past); Cue Biopharma, Inc. (Director · Oct 3, 2019 – Jan 3, 2023 · Past); SWK Holdings Corp (Director · Sep 3, 2019 – Dec 31, 2021 · Past) | Chairman · Since at least Aug 12, 2024 |
| Jason Keyes Other companies: BlossomHill Therapeutics, Inc. (Executive Vice President and Chief Financial Officer · Since at least Aug 6, 2026); Sesen Bio Inc (Director · Feb 24, 2020 – Jun 22, 2022 · Past); Equillium, Inc. (Chief Financial Officer · Oct 11, 2018 – Feb 14, 2025 · Past); Orexigen Therapeutics Inc (EVP, Chief Financial Officer · Jun 8, 2016 – Oct 13, 2017 · Past) | Director · Since at least Aug 12, 2024 |
| Martin H Huber Jr Other companies: Syndax Pharmaceuticals, Inc. (Director · Since at least Sep 15, 2021); Mersana Therapeutics Inc (President, CEO, Director · Since at least Apr 13, 2020); Xilio Therapeutics, Inc. (PRESIDENT AND HEAD OF R&D · Oct 21, 2021 – Aug 16, 2023 · Past); Tesaro Inc (SVP & Chief Medical Officer · Sep 21, 2015 – Jan 22, 2019 · Past) | Director · Since at least May 1, 2026 |
| Roger Sawhney Other companies: Adlai Nortye Group Ltd. (Independent Director · Since at least Mar 18, 2026); Arbutus Biopharma Corporation (Director · Since at least Aug 4, 2025); Alimera Sciences Inc (Director · Feb 25, 2023 – Feb 25, 2023 · Past); Omega Therapeutics Inc (Chief Financial Officer · Jul 29, 2021 – Mar 9, 2022 · Past) | Director · Since at least Aug 12, 2024 |
| Leslie W Kreis Other companies: Cognition Therapeutics, Inc. (Director · Since at least Jun 10, 2022); IN8bio, Inc. (Director · Aug 16, 2022 – Dec 12, 2022 · Past); Lantern Pharma Inc. (Director · Jun 10, 2020 – Mar 17, 2022 · Past) | Director · Since at least Jun 27, 2025 |
| Todd Thomson Other companies: ZOOZ Strategy Ltd. (Director · Since at least Mar 18, 2026); Dragonfly Energy Holdings Corp (Director · Aug 10, 2021 – Aug 10, 2021 · Past); Cordia Bancorp Inc (Director · Mar 29, 2013 – Aug 31, 2016 · Past) | Director · Since at least Aug 12, 2024 |
| Paul Lytle Other companies: Mosaic ImmunoEngineering Inc (EVP, Chief Financial Officer, Director · Since at least Aug 21, 2020); Avid Bioservices Inc (Chief Financial Officer · Feb 15, 2006 – Apr 28, 2017 · Past) | Chief Financial Officer · Since at least Aug 12, 2024 |
| Amy Ronneberg Other companies: Dianthus Therapeutics, Inc. (Director · Jun 20, 2018 – Jun 28, 2022 · Past) | Director · Since at least Aug 12, 2024 |
| Andrew Paul Mazar Other companies: Monopar Therapeutics Inc. (Chief Scientific Officer, Director · Jan 8, 2018 – Mar 31, 2022 · Past) | Chief Operating Officer · Since at least Aug 12, 2024 |
| Dan Zabrowksi Other companies: Apexigen Inc. (Director · Jul 29, 2022 – Aug 23, 2023 · Past) | Director · Since at least Aug 12, 2024 |
All 13 people
| Person | Seat |
|---|---|
| Daniel M. Schmitt | President & Chief Executive Officer · Since at least Aug 12, 2024 |
| Daniel Zabrowski | Director · Since at least Nov 4, 2026 |
| Martin Huber | Director · Since May 6, 2026 |
Log in to ask 6ix AI your own questions about Actuate Therapeutics, Inc.